A Native Mass Spectrometry-Based Assay for Rapid Assessment of the Empty:Full Capsid Ratio in Adeno-Associated Virus Gene Therapy Products

Lisa Strasser, Tomos E. Morgan, Felipe Guapo, Florian Füssl, Daniel Forsey, Ian Anderson, and Jonathan Bones*

ABSTRACT: Adeno-associated virus (AAV)-based gene therapy is a rapidly developing field, requiring analytical methods for detailed product characterization. One important quality attribute of AAV products that requires monitoring is the amount of residual empty capsids following downstream processing. Traditionally, empty and full particles are quantified via analytical ultracentrifugation as well as anion exchange chromatography using ultraviolet or fluorescence detection. Here, we present a native mass spectrometry-based approach to assess the ratio of empty to full AAV-capsids without the need for excessive sample preparation. We report the rapid determination of the relative amount of empty capsids in AAV5 and AAV8 samples. The results correlate well with more conventional analysis strategies, demonstrating the potential of native mass spectrometry for the characterization of viral particles.

Adeno-associated virus (AAV)-based gene therapy is evolving rapidly. Since the first AAV-based product was approved by the European Medicine Agency (EMA) in 2012, more than 150 AAV-related clinical trials have been listed on clinicaltrials.gov. However, despite this impressive progress, analytical methods to monitor quality attributes of recombinant AAV (rAAV)-based products have not advanced with the same speed.

AAVs are composed of a protein capsid that encapsulates a ∼4.7 kb single-stranded DNA genome. The capsid is assembled by 60 copies of the viral proteins VP1, VP2, and VP3 in a ratio of approximately 1:1:10, building a capsid of ∼3.8 MDa. Of particular concern during the production of rAAV is the amount of empty capsids present, which is not only important for administering the correct dosage but also to account for concerns regarding potential unwanted immune responses caused by empty capsids. There are various methods available to quantify the amount of empty and full capsids, the most common being analytical ultracentrifugation (AUC) as well as anion-exchange chromatography (AEX). While these tools have been shown to successfully separate empty and full capsids of various serotypes, absorbance-based methods still face certain limitations. Even though UV detection at 260 and 280 nm can be used to differentiate between empty and full capsids, respectively, during AEX separation, it is known to lack the required sensitivity that is of key importance when working with AAV samples of low concentration. Furthermore, a response factor is needed for correction during quantitation using UV absorbance. This can be avoided using fluorescence detection which, however, does not allow for an unambiguous identification of empty and full capsids. This problem could potentially be circumvented using a mass spectrometry (MS)-based approach.

In recent years, the application of mass spectrometry for the analysis of AAV particles has gained an increasing interest. Intact native MS analysis allowed for the determination of the molecular mass of AAV capsids and also revealed the enormous inherent heterogeneity of viral particles. This heterogeneity in combination with the high molecular weight of intact AAV capsids poses significant analytical challenges. Conventional non-isotopically resolving MS requires the detection and resolution of multiple consecutive charge states for deconvolution and, is therefore, only applicable to samples of limited complexity. While the use of native conditions results in less charges and a higher spatial resolution in the m/z dimension, it is currently not still possible to gain charge state resolution for intact AAV capsids.

Received: July 6, 2021
Accepted: August 24, 2021
Published: September 14, 2021
Even though it is not yet fully commercially available, charge detection mass spectrometry (CDMS) addresses this problem by directly measuring the mass of individual ions, enabling the analysis of high molecular weight species at a level that has not previously been possible.\textsuperscript{15−18} Interestingly, CDMS analysis has shown that empty and full AAV capsid particles have a similar charge state distribution, yet differ significantly in their mass.\textsuperscript{16,19} Here, we exploit this information to determine the empty:full ratio of rAAVs using conventional MS under native conditions. Observed signal clusters derived from empty and full AAV capsids were assigned and facilitated area-based quantification, resulting in an easy-to-implement assay that utilizes standard instrumentation readily available in many characterization laboratories.

\section*{RESULTS AND DISCUSSION}

Empty and full AAV5 were analyzed by native direct infusion mass spectrometry, resulting in signal clusters in the range of $m/z$ 18 000–23 000 and 23 000–32 500, respectively (Figure 1a and b). Importantly, empty reference material might contain full capsids and vice versa, resulting in an additional signal cluster as can be seen in Figure 1a ($m/z > 23 000$). Despite this, full and empty capsids appeared to follow the trend previously obtained by CDMS and appeared in different $m/z$ regions, indicating the same charge while being of different mass.\textsuperscript{16,19} Assuming an average charge state distribution from $+150$ to $+160$, as reported previously,\textsuperscript{19} the mass of empty AAV5 was found to be between 2.9 and 3.1 MDa, while full capsids appeared to have a mass of 3.8–4.1 MDa. Thus, the observed mass difference between full and empty particles correlates well with the mass of the incorporated cargo genome (2.5 kb, approximately 800 kDa). Notably, full capsids
appeared in a broader cluster, indicating higher heterogeneity due to the incorporated ssDNA.

Next, mixtures of full and empty AAV5 were analyzed. As shown in Figure 1c and d, corresponding to the respective 1:1 and 1:5 mixtures (V/V), observed signal clusters still appeared in the same m/z region, while the relative abundance changed. Interestingly, the spray stability during static nanoESI infusion was observed to differ considerably depending on the AAV serotype, with AAV5 being particularly difficult to analyze over extended periods of time. Whether this is due to the sample stability in ammonium acetate requires further investigations. Nevertheless, while the spray stability is a crucial factor during CDMS analysis where extensive data acquisition times are required, it did not noticeably affect the quality of the presented data, as acquisition times were merely 5 min per measurement. To the best of our knowledge, this is the first time spectra obtained from both empty and full AAV5 have been reported.

To test the method for its applicability for different serotypes, the same analysis was performed for AAV8. Figure 2 shows the results obtained for 1:1 and 1:5 mixtures of empty and full capsids of AAV8. The acquired charge upon ionization caused shifts in the m/z distribution that are dependent on the serotype. Therefore, AAV8 generally appeared at a higher m/z range, but the intensities corresponding to full and empty particles still changed according to their concentration.

Importantly, the analyses performed did not result in charge state resolution and therefore do not allow for a direct determination of the accurate masses of AAV5 and AAV8. However, differential signal clusters were clear and allowed for the relative quantification of the amount of full and empty capsids. To determine the empty to full ratio of the analyzed samples, corresponding cluster areas were measured using ImageJ. Resulting data were exported for further analysis, and the results obtained are shown in Table 1.

As indicated in Table 1, a volumetric mixture of the empty and full reference material in a ratio of 1:1 was found to contain approximately 60% full capsids, while a 1:5 mixture contained about 82% full capsids, which correlates well with what was expected. Furthermore, the obtained results agree with numbers obtained by fluorescence detection using AEX separation (below 5% variation, data shown in Supplementary Figure 1). The reproducibility of the native MS analysis was evaluated by triplicate analysis of AAV5 samples (Figure S2 and Table S1 in the Supporting Information). The standard deviation was found to be below 1.05%, indicating a high consistency. This clearly demonstrates that conventional MS under native conditions can be used to reliably assess the empty to full ratio of AAV samples. Further modifications of the presented method, such as the use of charge reduction to increase the spatial resolution, might also enable the quantification of the amount of partially filled capsids. In any case, the required analysis time is significantly lower compared to that of standard AEX, and the MS analysis furthermore allowed for an unambiguous assignment of signals to full and empty capsids without the need for further experiments in addition to a reliable evaluation of their relative abundances.

Finally, to demonstrate the applicability of the presented method for samples derived from downstream processing, an in-process sample of AAV5 was analyzed (Figure 3). 53.45% of capsids were found to be full, resulting in an empty:full ratio of 1.15. Results correlate with the amount of full capsids determined via AUC, which was carried out by Pharmaron (data not shown).

**Table 1. Empty to Full Ratio Assessment of AAV5 and AAV8**

| sample | empty:full (V:V) | ratio | % full (MS) | % full (AEX) |
|--------|-----------------|-------|-------------|--------------|
| AAV5   | 1:1             | 1.56  | 61.02%      | 62.66%       |
| AAV5   | 1:5             | 4.60  | 82.16%      | 77.54%       |
| AAV8   | 1:1             | 1.41  | 58.50%      | 58.21%       |
| AAV8   | 1:5             | 3.28  | 76.62%      | 73.94%       |

“AAV reference material was mixed in a ratio of either 1:1 or 1:5. Samples were analyzed via native MS, and the resulting data were analyzed using ImageJ. Signal clusters corresponding to empty and full capsids were measured and subsequently used to calculate the ratio of empty to full as well as the percentage of full capsids. Additionally, empty and full capsids were separated using AEX, and peak areas were used to calculate the relative amount of full AAV in percent.”
**CONCLUSION**

Direct infusion native mass spectrometry was used to measure the relative abundance of AAV5 and AAV8 capsids with and without cargo DNA. Signal clusters derived from empty and full capsids were clearly differentiated, and their relative abundances correlated well with expected values based on the deliberate generation of samples with varying empty:full ratios. Importantly, the approach presented has shown applicability for multiple AAV serotypes, as well as samples derived from downstream processing. Taken together, the results presented clearly demonstrate the potential of using commercially available mass spectrometry for the analysis of critical quality attributes of high-molecular-weight analytes, such as AAVs. Although AAV charge states remained unresolved due to the sample size and complexity, m/z spacing of the filled and unfilled capsids allowed for relative quantification. Short acquisition times offer great prospect for the coupling of MS analysis strategies to chromatographic separation techniques and the potential for deeper and more accurate analyses will be enabled. Moreover, further establishment of charge detection MS (CDMS) methods will allow a more accurate mass determination of viral capsids. Further technological developments will fully enable the detailed characterization of next-generation biotherapeutics such as AAV.

**ASSOCIATED CONTENT**

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.analchem.1c02828.

Additional experimental details, materials, and methods about the MS analysis and AEX, results of the empty/full separation using AEX, and replicate analysis of AAVS using native MS analysis (PDF)

**AUTHOR INFORMATION**

**Corresponding Author**

Jonathan Bones — National Institute for Bioprocessing Research and Training (NIBRT), Dublin A94 X099, Ireland; School of Chemical and Bioprocess Engineering, University College Dublin, Dublin D04 V1W8, Ireland;

-orcid.org/0000-0002-8978-2592;

Phone: +35312158100; Email: jonathan.bones@nibrt.ie;

Fax: +35312158116

**Authors**

Lisa Strasser — National Institute for Bioprocessing Research and Training (NIBRT), Dublin A94 X099, Ireland

Tomos E. Morgan — National Institute for Bioprocessing Research and Training (NIBRT), Dublin A94 X099, Ireland

Felipe Guapo — National Institute for Bioprocessing Research and Training (NIBRT), Dublin A94 X099, Ireland

Florian Füssl — National Institute for Bioprocessing Research and Training (NIBRT), Dublin A94 X099, Ireland

Daniel Forsey — Pharmaron, Liverpool L24 8RB, United Kingdom

Ian Anderson — Pharmaron, Liverpool L24 8RB, United Kingdom

Complete contact information is available at: https://pubs.acs.org/10.1021/acs.analchem.1c02828

**Author Contributions**

The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.

**Notes**

The authors declare no competing financial interest.

**ACKNOWLEDGMENTS**

The authors greatly acknowledge funding from Enterprise Ireland under the Innovation Partnership Program IP/2018/0753 and support from Abbvie and Pharmaron.

**REFERENCES**

(1) Wang, D.; Tai, P. W. L.; Gao, G. Nat. Rev. Drug Discovery 2019, 18, 358–378.

(2) Vandenberghe, L. H.; Wilson, J. M.; Gao, G. Gene Ther. 2009, 16, 311–319.

(3) Gao, K.; Li, M.; Zhong, L.; Su, Q.; Li, J.; Li, S.; He, R.; Zhang, Y.; Hendricks, G.; Wang, J.; Gao, G. Mol. Ther.–Methods Clin. Dev. 2014, 1, 9.

(4) Fussl, F.; Trappe, A.; Cook, K.; Scheffler, K.; Fitzgerald, O.; Bones, J. MAbs 2019, 11, 116–128.

(5) Li, T.; Gao, T.; Chen, H.; Pekker, P.; Menyhart, A.; Gutmann, A. Curr. Mol. Med. 2021, 20, 814–820.

(6) Burnham, B.; Nass, S.; Kong, E.; Mattingly, M.; Woodcock, D.; Song, A.; Wadsworth, S.; Cheng, S. H.; Scaria, A.; O’Riordan, C. R. Hum. Gene Ther. Methods. 2015, 26, 228–242.

(7) Khatwani, S. L.; Pavlova, A.; Pirot, Z. Mol. Ther.–Methods Clin. Dev. 2021, 21, 548–558.

(8) Joshi, P. R. H.; Bernier, A.; Chabah, P. S.; Kamen, A. Hum. Gene Ther. 2021, DOI: 10.1089/hum.2020.317.

(9) Sommer, J. M.; Smith, P. H.; Parthasarathy, S.; Isaacs, J.; Vijay, S.; Kieran, J.; Powell, S. K.; McClelland, A.; Wright, J. F. Mol. Ther. 2003, 7, 122–128.

(10) Wang, C.; Mulagapati, S. H. R.; Chen, Z.; Du, J.; Zhao, X.; Xi, G.; Chen, L.; Linke, T.; Gao, C.; Schmelzer, A. E.; Liu, D. Mol. Ther.–Methods Clin. Dev. 2019, 15, 257–263.
(11) Dulfer, J.; Kadek, A.; Kopicki, J. D.; Krichel, B.; Uetrecht, C. Adv. Virus Res. 2019, 105, 189–238.
(12) Worner, T. P.; Shamorkina, T. M.; Snijder, J.; Heck, A. J. R. Anal. Chem. 2021, 93, 620–640.
(13) Worner, T. P.; Bennett, A.; Habka, S.; Snijder, J.; Friese, O.; Powers, T.; Agbandje-McKenna, M.; Heck, A. J. R. Nat. Commun. 2021, 12, 1642.
(14) Wohlschlager, T.; Scheffler, K.; Forstenlehner, I. C.; Skala, W.; Senn, S.; Damoc, E.; Holzmann, J.; Huber, C. G. Nat. Commun. 2018, 9, 1713.
(15) Todd, A. R.; Barnes, L. F.; Young, K.; Zlotnick, A.; Jarrold, M. F. Anal. Chem. 2020, 92, 11357–11364.
(16) Pierson, E. E.; Keifer, D. Z.; Asokan, A.; Jarrold, M. F. Anal. Chem. 2016, 88, 6718–6725.
(17) Kafader, J. O.; Melani, R. D.; Durbin, K. R.; Ikwuagwu, B.; Early, B. P.; Fellers, R. T.; Beu, S. C.; Zabrouskov, V.; Makarov, A. A.; Maze, J. T.; Shinholt, D. L.; Yip, P. F.; Tullman-Ercek, D.; Senko, M. W.; Compton, P. D.; Kelleher, N. L. Nat. Methods 2020, 17, 391–394.
(18) Elliott, A. G.; Harper, C. C.; Lin, H. W.; Williams, E. R. Analyst 2017, 142, 2760–2769.
(19) Worner, T. P.; Snijder, J.; Bennett, A.; Agbandje-McKenna, M.; Makarov, A. A.; Heck, A. J. R. Nat. Methods 2020, 17, 395–398.